SEC Comment Letter 0000000000-24-000988 to Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)
Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)
Date: Jan. 25, 2024 · CIK: 0001501756 · Accession: 0000000000-24-000988
AI Filing Summary & Sentiment
File numbers found in text: 001-36579
Letter
United States securities and exchange commission logo January 25, 2024 Linda Rubinstein Chief Financial Officer Adverum Biotechnologies, Inc. 100 Cardinal Way Redwood City , CA Re:Adverum Biotechnologies, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 Filed March 30, 2023 File No. 001-36579 Dear Linda Rubinstein: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
January 25, 2024
Linda Rubinstein
Chief Financial Officer
Adverum Biotechnologies, Inc.
100 Cardinal Way
Redwood City , CA
Re:Adverum Biotechnologies, Inc.
Form 10-K for Fiscal Year Ended December 31, 2022
Filed March 30, 2023
File No. 001-36579
Dear Linda Rubinstein:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences